Septerna, Inc. (NASDAQ:SEPN) Stock Has Consensus Price Target of $53.67 According to Brokerages

Shares of Septerna, Inc. (NASDAQ:SEPN) have received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $56.44.

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. increased their target price on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Wells Fargo & Company boosted their price target on Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Stifel Nicolaus upped their price target on shares of Septerna from $49.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday. JonesTrading upped their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, HC Wainwright increased their price objective on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th.

Septerna Trading Down 7.2%

Shares of SEPN opened at $48.56 on Thursday. The firm has a market cap of $2.27 billion, a PE ratio of -37.64 and a beta of 2.20. The firm has a fifty day simple moving average of $40.26 and a two-hundred day simple moving average of $32.95. Septerna has a 1-year low of $18.64 and a 1-year high of $53.34.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). Septerna had a negative return on equity of 14.98% and a negative net margin of 61.29%. The firm had revenue of $18.88 million during the quarter, compared to analysts’ expectations of $20.78 million. As a group, research analysts forecast that Septerna will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Long sold 3,333 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently modified their holdings of SEPN. Sterling Capital Management LLC raised its holdings in Septerna by 215.0% in the 3rd quarter. Sterling Capital Management LLC now owns 630 shares of the company’s stock worth $25,000 after purchasing an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Septerna during the third quarter valued at $93,000. Covestor Ltd lifted its position in Septerna by 19.0% during the third quarter. Covestor Ltd now owns 2,526 shares of the company’s stock valued at $98,000 after purchasing an additional 403 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Septerna during the second quarter valued at about $211,000. Finally, Canada Pension Plan Investment Board bought a new stake in Septerna during the second quarter valued at about $298,000.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.